Endocrine Abstracts

Introduction: In Spain, the specialist in endocrinology and nutrition is the reference in the care of patients with diabetes mellitus. In the year 2022, access to these specialists has been facilitated in the south of Gran Canaria. The aim of the study is to determine how this has influenced the management of type 2 diabetes (T2D).

Methods: We included those patients with T2D assessed by the Endocrinology service in 2022 in which two analyses were performed 6 months apart. Patients diagnosed with T2D in 2022 or who had been assessed by an endocrinologist after July 2021 were excluded. The change in glycosylated haemoglobin (HbA1c) and LDLc was assessed in all patients and by subgroups. The change in anti-diabetic and lipid-lowering treatment was studied. In addition, we analysed the influence on metabolic control of the introduction of basal insulin, iSGLT2, aGLP1 and assessment by the hospital dietician team.

Results: A total of 77 patients were included, 58.41% were male. The mean duration of diabetes was 12.28 years. 76.62% were in primary prevention. The change in HbA1c, expressed in%, with basal insulin initiation (4 patients), iSGLT2 (16 patients), aGLP1 (16 patients) and assessment by dietician (13 patients) was 10.45±1.67 vs 7.33±1.12 (P=0.125), 7.981±1.44 vs 6.694±0.73 (P=0.0004), 8.33±1.71 vs 6.687±0.80 (P=0.0002) and 7.523±1.84 vs 6.646±0.83 (P=0.415), respectively.

Conclusion: Patients with T2D managed by endocrinologists have improved metabolic and lipid profile control. There has been a marked increase in the use of iSGLT2, aGLP1 and statins, as recommended in disease management guidelines. The introduction of iSGLT2 and aGLP1 achieved a statistically significant decrease in HbA1c.